Organization
UCB Pharma, Slough, United Kingdom
8 abstracts
Abstract
ASSOCIATION BETWEEN PATIENT-REPORTED OUTCOMES AND DISEASE ACTIVITY IN BIMEKIZUMAB-TREATED PATIENTS WITH PSORIATIC ARTHRITISOrg: Sorbonne Université and Pitié Salpétriere Hospital, Paris, France, Swedish Medical Center and University of Washington, Seattle, United States of America, Icahn School of Medicine at Mount Sinai, New York, United States of America, Hospital of the University of Pennsylvania, Philadelphia, United States of America, UCB Pharma, Slough, United Kingdom,
Abstract
ATTITUDES OF PATIENTS AND PHYSICIANS IN THE TREATMENT OF RHEUMATOLOGICAL DISEASE DURING PREGNANCY Org: Lupus Research Unit, The Rayne Institute, London, UCB Pharma, Slough, United Kingdom, Oklahoma Medical Research Foundation, Oklahoma City, United States,
Abstract
A SINGLE DETERMINATION OF C-REACTIVE PROTEIN DOES NOT SUFFICE TO DECLARE A PATIENT WITH A DIAGNOSIS OF AXIAL SPA “CRP-NEGATIVE” Org: Clinical Immunology and Rheumatology, Amsterdam Rheumatology & Immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, UCB Pharma, Monheim, Germany, UCB Pharma, Slough, United Kingdom,
Abstract
ACHIEVEMENT OF REMISSION OF INFLAMMATION IN THE SPINE AND SACROILIAC JOINTS MEASURED BY MAGNETIC RESONANCE IMAGING (MRI) IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, AND ASSOCIATIONS BETWEEN MRI AND CLINICAL REMISSION, OVER 96 WEEKS OF TREATMENT WITH CERTOLOrg: Rheumazentrum Ruhrgebiet, Herne, Germany, Department of Medicine, University of Alberta, Alberta, Canada, Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands, Ruhr-University Bochum, Herne, Charité Medical School, Berlin, Germany,
Abstract
ACHIEVEMENT OF VERY LOW DISEASE ACTIVITY AND REMISSION TREATMENT TARGETS IS ASSOCIATED WITH REDUCED RADIOGRAPHIC PROGRESSION IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOLOrg: UCB Pharma, Slough, United Kingdom, UCB Pharma, Monheim am Rhein, Germany,
Abstract
BIMEKIZUMAB MAINTAINED EFFICACY RESPONSES THROUGH 52 WEEKS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM TWO PHASE 3 STUDIESOrg: Royal National Hospital of Rheumatic Diseases, Bath, United Kingdom, Centre for Therapeutic Innovation, University of Bath, Department of Life Sciences, Bath, United Kingdom, University of Occupational and Environmental Health, The First Department of Internal Medicine, Kitakyushu, Fukuoka, Japan, Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, UCB Pharma, Slough, United Kingdom,
Abstract
BIMEKIZUMAB-TREATED PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS SHOWED SUSTAINED ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY AND REMISSION: UP TO 2-YEAR RESULTS FROM TWO PHASE 3 STUDIESOrg: Nuffield Orthopaedic Centre, Oxford, United Kingdom, Oxford University Hospitals NHS Trust, University of Oxford and Oxford Biomedical Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases, Oxford, United Kingdom, Copenhagen University Hospital, The Parker Institute, Bispebjerg and Frederiksberg, Denmark, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America, Royal National Hospital of Rheumatic Diseases, Bath, United Kingdom,
Abstract
BIMEKIZUMAB IMPACT ON CARDIOVASCULAR INFLAMMATION MARKERS IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM PHASE 3 TRIALSOrg: Psoriasis Research and Treatment Center, Clinic of Dermatology, Venereology, and Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, United Kingdom, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, Dalhousie University, Halifax, Nova Scotia, Canada, St Vincent’s University Hospital, Elm Park and the Charles Institute, University College Dublin, Dublin, Ireland,